Enhancement of Allele Discrimination by Introduction of Nucleotide Mismatches into siRNA in Allele-Specific Gene Silencing by RNAi

Yusuke Ohnishi1,2, Yoshiko Tamura1, Mariko Yoshida1, Katsushi Tokunaga2, Hirohiko Hohjoh1*

1 Department of Molecular Genetics, National Institute of Neuroscience, NCNP, Kodaira, Tokyo, Japan, 2 Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Abstract
Allele-specific gene silencing by RNA interference (RNAi) is therapeutically useful for specifically inhibiting the expression of disease-associated alleles without suppressing the expression of corresponding wild-type alleles. To realize such allele-specific RNAi (ASP-RNAi), the design and assessment of small interfering RNA (siRNA) duplexes conferring ASP-RNAi is vital; however, it is also difficult. In a previous study, we developed an assay system to assess ASP-RNAi with mutant and wild-type reporter alleles encoding the Photinus and Renilla luciferase genes. In line with experiments using the system, we realized that it is necessary and important to enhance allele discrimination between mutant and corresponding wild-type alleles. Here, we describe the improvement of ASP-RNAi against mutant alleles carrying single nucleotide variations by introducing base substitutions into siRNA sequences, where original variations are present in the central position. Artificially mismatched siRNAs or short-hairpin RNAs (shRNAs) against mutant alleles of the human Prion Protein (PRNP) gene, which appear to be associated with susceptibility to prion diseases, were examined using this assessment system. The data indicates that introduction of a one-base mismatch into the siRNAs and shRNAs was able to enhance discrimination between the mutant and wild-type alleles. Interestingly, the introduced mismatches that conferred marked improvement in ASP-RNAi appeared to be largely present in the guide siRNA elements, corresponding to the ‘seed region’ of microRNAs. Due to the essential role of the ‘seed region’ of microRNAs in their association with target RNAs, it is conceivable that disruption of the base-pairing interactions in the corresponding seed region, as well as the central position (involved in cleavage of target RNAs), of guide siRNA elements could influence allele discrimination. In addition, we also suggest that nucleotide mismatches at the 3′-ends of sense-strand siRNA elements, which possibly increase the assembly of antisense-strand (guide) siRNAs into RNA-induced silencing complexes (RISCs), may enhance ASP-RNAi in the case of inert siRNA duplexes. Therefore, the data presented here suggest that structural modification of functional portions of an siRNA duplex by base substitution could greatly influence allele discrimination and gene silencing, thereby contributing to enhancement of ASP-RNAi.

Citation: Ohnishi Y, Tamura Y, Yoshida M, Tokunaga K, Hohjoh H (2008) Enhancement of Allele Discrimination by Introduction of Nucleotide Mismatches into siRNA in Allele-Specific Gene Silencing by RNAi. PLoS ONE 3(5): e2248. doi:10.1371/journal.pone.0002248

Editor: Luis M. Corrochano, University of Sevilla, Spain
Received November 1, 2007; Accepted April 14, 2008; Published May 21, 2008

Copyright: © 2008 Ohnishi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by research grants from the Ministry of Health, Labor, Welfare in Japan, and from Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists, and also by a Grant-in-Aid from the Japan Society for the Promotion of Science.

Competing Interests: The corresponding author has a pending patent on the method used in this study.

* E-mail: hohjohh@ncnp.go.jp

Introduction
RNA interference (RNAi) is the process of sequence-specific posttranscriptional gene silencing induced by double-stranded RNAs (dsRNAs) homologous to the silenced gene, and it is currently used as a powerful tool to suppress the expression of genes of interest [1,2]. Introduced or generated dsRNAs are subjected to digestion by an RNase III enzyme, Dicer, into 21–25 nucleotide (nt) RNA duplexes [3]. The resultant RNA duplexes, referred to as small interfering RNA (siRNA) duplexes, are unwound, and single-stranded siRNA elements can then be incorporated into RNA-induced silencing complexes (RISCs) to function as sequence-specific mediators. These are referred to as guide siRNA elements [1,2,4].

In mammals, RNAi can be induced by direct introduction of chemically synthesized siRNA duplexes into cells, or by generation of siRNA duplexes using short-hairpin RNA (shRNA) expression vectors. Applications are expanding in various fields of science, with the potential therapeutic use of RNAi in medical science and pharmacogenetics being particularly promising [1,5–8].

Allele-specific gene silencing by RNAi (allele-specific RNAi: ASP-RNAi) is an advanced application of RNAi techniques that allows the expression of an allele of interest to be specifically inhibited [9]. ASP-RNAi would thus be therapeutically very useful, as it can specifically suppress the expression of alleles causing disease without inhibiting the expression of corresponding wild-type alleles [10–17]. To induce such ASP-RNAi, it is necessary to design siRNAs that exhibit strong allele-specific gene silencing; thus, siRNAs must be designed such that they are able to carry nucleotide variations characterizing target disease alleles and to discriminate the target alleles from corresponding wild-type alleles. In addition, qualitative and quantitative evaluation of such designed siRNAs on allele-specific gene silencing is required.

In a previous study, we developed an assay system to assess ASP-RNAi with mutant and wild-type reporter alleles encoding...
the Photinus and Renilla luciferase genes. In this system, the effects of designed siRNAs and short-hairpin RNAs (shRNAs) against mutant alleles in allele-specific gene silencing, as well as off-target silencing against wild-type alleles, can be simultaneously examined [17]. With amyloid precursor protein (APP) variants (the Swedish- and London-type variants) related to familial Alzheimer’s disease [18,19] as model disease alleles, we were able to determine competent siRNA duplexes conferring ASP-RNAi [17]. Previous observations have also suggested that enhanced discrimination of target mutant alleles carrying single nucleotide variations from wild-type allele RNAs is required for ASP-RNAi.

In the present study, we describe the improvement of ASP-RNAi against mutant alleles carrying single nucleotide variations. We introduced base substitutions into siRNA and shRNA sequences, and examined the effects of the resultant mismatched siRNAs and shRNAs on ASP-RNAi by means of our assay system. The results presented here suggest that base substitutions introduced into certain portions of siRNA and shRNA sequences may contribute to enhancement of ASP-RNAi.

Results

ASP-RNAi against PRNP alleles carrying single nucleotide variations

In a previous study, we established an assessment system for siRNA duplexes carrying ASP-RNAi [17]. This system depends on two reporter alleles encoding the Photinus and Renilla luciferase genes carrying mutant and wild-type allelic sequences in their 3’-UTRs. Briefly, using this system, the effects of test siRNA duplexes against mutant alleles in allele-specific silencing, as well as off-target silencing against wild-type alleles, can be examined under heterogeneous conditions generated by cotransferring the reporter alleles and siRNA duplexes into cultured human cells.

In this study, we focused on the human Prion Protein (PRNP) gene, which is known to possess a number of single nucleotide variations [20,21]. We selected three PRNP variants, which are also followed by amino acid substitutions [P102L, P105L, and D178N] and appear to be associated with susceptibility to various prion diseases such as Gerstmann-Strassler-Scheinker disease (GSS) and fatal familial insomnia (FFI) [22–25]. We constructed three mutant reporter alleles, designated the PRNP-P102L, PRNP-P105L, and PRNP-D178N alleles, and their corresponding wild-type reporter alleles (Figure 1A). The reporter alleles, synthetic siRNA duplexes against the mutant alleles (supplementary Table s1 and supplementary Figure s1), and the beta-galactosidase gene (control), were cotransfected into HeLa cells; thus, the transfected cells were artificially heterozygous with the mutant and wild-type reporter alleles. The effects of the designed siRNA duplexes on suppression of both the mutant and wild-type alleles were then simultaneously examined. As shown in Figure 1, the siRNA duplexes other than siPrnp102(T7), siPrnp102(T8), siPrnp105(T7) and siPrnp105(T9) were not able to induce significant ASP-RNAi. Of the four siRNAs just listed, the siPrnp105(T9) duplex appears to confer ASP-RNAi.

To realize ASP-RNAi against any target alleles, it is important and necessary to establish techniques for enhancement of allele discrimination followed by specific digestion against the target alleles. To address this, we selected siRNA duplexes possessing strong knockdown potency as candidates for improvement. This is because the only apparent failure of such siRNAs is being unable to discriminate target alleles from non-target ones, i.e., ASP-RNAi may be improved just by reinforcing allele discrimination. Since RNAi activity appears to be influenced by nucleotide mismatches
between siRNAs and their target RNAs [11,26], we introduced a one-base substitution into the selected siRNAs (Figures 2A and E; supplementary Table s2) and examined the effects of such mismatched siRNA duplexes using our assessment system. It should be noted that the resultant mismatched siRNAs give rise to one nucleotide mismatches against the target mutant allele, and more importantly, two nucleotide mismatches against the wild-type allele (the artificially introduced mismatch and the original variation). Accordingly, we expected that such mismatched siRNAs would exhibit better discrimination between target mutant and wild-type alleles, and only suppress the expression of the mutant alleles.

Effects of mismatched siRNA duplexes on ASP-RNAi against PRNP-P102L and PRNP-P105L alleles

We selected the siPrnp102(T9) and siPrnp105(T10) duplexes from the first screening of siRNA duplexes against the PRNP mutant alleles (Figure 1), and introduced base substitutions into the siRNAs (Figures 2A and E). The resultant mismatched siRNAs were investigated using the assessment system to determine whether they could improve ASP-RNAi. Data are averages of at least three independent determinations. Error bars represent standard deviations. Expression of the wild-type (C, G) and mutant [P102L (D) and P105L (H)] PRNP polypeptides (PRNPmut102-V5 and PRNPmut105-V5) in the presence of indicated siRNA duplexes was investigated by Western blotting using anti-V5 antibody. Expression of α-tubulin was examined as the control.

doi:10.1371/journal.pone.0002248.g002

Figure 2. Assessment of mismatched siPrnp102(T9) and siPrnp105(T10) duplexes on ASP-RNAi. (A, E) Nucleotide sequences of wild-type and mutant PRNP mRNAs and designed siRNAs. The wild-type and mutant PRNP mRNA sequences around the P102L (A) and P105L (E) variations are shown and the variations are indicated in red. Designed siRNAs (indicated) are represented based on the sequence of the sense-strand (passenger) siRNA element; mismatched nucleotides (introduced base substitutions) and the original variations are indicated in blue and red, respectively. The same sequences as the siPrnp102(T9) or siPrnp105(T10) are represented by thin lines. (B, F) Effects of mismatched siPrnp102(T9) and siPrnp105(T10) on ASP-RNAi. Mismatched siPrnp102(T9) (B) and siPrnp105(T10) (E) duplexes (indicated) were examined as in Figure 1. The ratio of wild-type allele-luciferase activity against the mutant allele-luciferase activity (WT/Mut) was also examined to evaluate the improvement in ASP-RNAi. Data are averages of at least three independent determinations. Error bars represent standard deviations. Expression of the wild-type (C, G) and mutant [P102L (D) and P105L (H)] PRNP polypeptides (PRNPmut102-V5 and PRNPmut105-V5) in the presence of indicated siRNA duplexes was investigated by Western blotting using anti-V5 antibody. Expression of α-tubulin was examined as the control.

doi:10.1371/journal.pone.0002248.g002
tively. The results indicate that: (i) introduction of a one-base substitution into the siRNAs was able to influence allele discrimination and RNAi activity, (ii) different nucleotide mismatches appeared to yield different levels of discrimination and inhibition against either the target mutant or wild-type allele, and (iii) some base substitutions appeared to confer marked allele discrimination, resulting in enhancement of ASP-RNAi. It may be of interest that the expression level of the wild-type allele in the presence of siPrnp105(T10)-14U was markedly increased, which may have been caused by the unusual expression level of the control *beta-galactosidase* gene, for as yet unknown reasons. Examination of the ratio of wild-type expression to mutant expression revealed that the siPrnp102(T9)-12C, -13A, -14U and -17G duplexes (Figure 2B) and the siPrnp105(T10)-14U and -15U duplexes (Figure 2F) appear to have markedly improved ASP-RNAi activity. In addition, when HEK293 cells were used instead of HeLa cells, similar results were obtained (data not shown).

To further confirm the results, we examined the effects of the siRNAs on the recognition and inhibition of the *bona fide* wild-type and mutant *PRNP* alleles using their full-length cDNAs. The *pPRNPwt-V5* and *pPRNPmut102* (or *mut105-V5*) expression plasmids carrying the wild-type and mutant cDNAs, respectively, were subjected to cotransfection with the siRNAs into HeLa cells, and the expression of the *PRNPwt-V5* or the *PRNPmut102* (or *mut105-V5*) polypeptide then examined by Western blotting. The results indicate that while the signal of *PRNPwt-V5* in the presence of siPrnp102(T9) or siPrnp105(T10) was reduced, the signal intensity of *PRNPwt-V5* was increased in the presence of either siPrnp102(T9)-12C, siPrnp102(T9)-14U or siPrnp105(T10)-15U (Figures 2C and G; supplementary Figure s2A). As expected, the mismatched siRNAs still hold a strong knockdown potency against the mutant *PRNP* (Figures 2D and H; supplementary Figure s2B). These observations agree with the results for the reporter alleles described above.

**Effects of mismatched siRNA duplexes on ASP-RNAi against *PRNP* mutant alleles**

From the first screening (Figures 1C and D), we also selected the siPrnp102(T10) and siPrnp178(A9) duplexes and introduced base substitutions into the siRNAs (supplementary Figures s3A and D). Assessment of the mismatched siRNAs suggested that, similar to Pmrp102(T9) and Pmrp105(T10), introduction of a one-base substitution into the siRNAs influenced ASP-RNAi activity. Furthermore, the ratios of wild-type allele expression to mutant allele expression indicated that the siPrnp102(T10)-13C and siPrnp178(A9)-13C duplexes have significantly improved ASP-RNAi activity (supplementary Figures s3B and E). Western blot analysis indicated that while the *PRNPwt-V5* signal was reduced in the presence of either siPrnp102(T10) or siPrnp178(A9), the signal was increased in the presence of the mismatched siPrnp102(T10)-13C or siPrnp178(A9)-13C duplexes (supplementary Figures s3C and F); thus, the data is also compatible with the results for the reporter alleles described above.

**Effects of shRNA expression plasmids on ASP-RNAi**

As short-hairpin RNA (shRNA) expression vectors appear to be useful for long-term gene silencing [16,27,28], their potential use in ASP-RNAi is also of interest. We constructed shRNA expression plasmids for production of the siPrnp102(T9), (T9)-12C, (T9)-13A, (T9)-14U and (T9)-15U duplexes in cells [designated sh102(T9), sh102(T9)-12C, sh102(T9)-13A, sh102(T9)-14U, sh102(T9)-15U plasmids, respectively]. The shRNA expression plasmids were examined by the assay system and Western blotting as described above. As shown in Figure 3, the results indicate that while the sh102(T9) plasmid induced strong gene silencing against either the mutant or wild-type allele, the sh102(T9)-12C, -13A, -14U and -15U plasmids were able to confer allele-specific gene silencing, which agrees with the data for synthetic siRNA duplexes (Figure 2). It is noteworthy that the mismatched shRNA expression plasmids appear to enhance ASP-RNAi to a greater degree than the corresponding synthetic siRNA duplexes; of the mismatched plasmids, the sh102(T9)-12C plasmid, appears to induce strong ASP-RNAi. It is possible that mismatched shRNA expression plasmids are superior to mismatched siRNA duplexes for induction of ASP-RNAi.

**Effects of structural modification of siRNA duplexes on ASP-RNAi**

In a previous study, we experienced difficulty in inducing ASP-RNAi against the London-type amyloid precursor protein (*APP*) mutants, in which single nucleotide substitutions followed by amino acid substitutions (*V717I, V717L, V717G*) were present [17]. While a few designed siRNAs targeting the mutants appeared to discriminate between the mutant and the corresponding wild-type alleles to some degree, most of the siRNAs resulted in weak gene silencing. This is in contrast to the knockdown potency of siRNAs targeting the *PRNP* mutants described above (Figure 1). To
improve such ASP-RNAi, it is necessary to design siRNAs such that they can gain knockdown potency against the mutants, and structural modification may also be applicable for achieving such improvements.

Previous studies showed that fork-siRNA duplexes (F-siRNA duplexes) carrying two nucleotide mismatches at the 3'-ends of the sense-strand siRNA elements are able to enhance RNAi activity to a greater degree than conventional siRNA duplexes [29,30]. Accordingly, we investigated whether F-siRNA duplexes improve ASP-RNAi activity against the London-type APP mutants (Figure 4 and supplementary Table s5). The results indicate that several F-siRNA duplexes [F-siAPP(A11), (T11), (G11) and (G12)] were able to enhance ASP-RNAi to some degree (Figures 4B-D).

In relation to the improvement of ASP-RNAi against the London-type APP mutants, we further observed that F-siRNA duplexes, F-siAPP(T12/C13), targeting the Swedish APP mutant carrying double nucleotide mutations, were able to markedly improve ASP-RNAi activity, although the conventional siAPP(T12/C13) duplexes induced little or no RNAi activity (Figure 4E).

Different effects of miR-196a and miR-196b on recognition of target HOXB8

From the data of the mismatched siPrnp duplexes (Figures 2 and supplementary Figures s2 and s3) and shPrnp RNAs (Figure 3), it appears that the base substitutions conferring marked improvement are largely present in the region of siRNAs corresponding to the seed region of microRNA. This suggests that the region corresponding to the seed region, as well as the central position (where the original variations are present), of guide siRNAs may play a role in allele discrimination in allele-specific gene silencing (details in Discussion). Based on this, it is of particular interest to determine whether the two regions of bona fide microRNA (miRNA) can contribute to the regulation of gene expression. From a previous study [31] and an miRNA database, we focused on miR-196a and miR-196b, both of which are nearly complementary to part of the 3'-UTR sequence of HOXB8 mRNA. Note that one and two mismatches are present in the predicted base-pairing of HOXB8 with miR-196a and miR-196b, respectively (Figure 5A). In addition, one mismatch, which can form a G:U wobble base-pair, is present in the seed region of both miRNAs, while the other mismatch (U vs. C) is present in the central position of miR-196b. We examined whether the mismatches in miR-196a and miR-196b participate in the recognition of their target, HOXB8.

To address this, we constructed a reporter plasmid encoding the Renilla luciferase gene with a part of the HOXB8 sequence in its 3'-UTR. The resultant reporter gene was cotransfected with either synthetic miR-196a or miR-196b duplex into HeLa cells, and the expression levels of the reporter gene then examined. The results (Figure 5B) indicate that miR-196a induced potent inhibition of the expression of the target reporter gene, whereas miR-196b conferred moderate levels of suppression against target reporter gene expression, thus suggesting different levels of recognition against HOXB8 between miR-196a and miR-196b. Consequently, the evidence suggests that the mismatches in miR-196a and miR-196b probably influence the recognition of their target HOXB8 mRNA.

Discussion

Enhancement of ASP-RNAi by mismatched siRNAs

In order to realize and control ASP-RNAi, it is necessary to design competent siRNAs or shRNAs possessing strong allele discrimination between target mutant and wild-type alleles, thereby inducing allele-specific gene silencing. In the case of ASP-RNAi, designed siRNAs perfectly match target mutant alleles, but do not correspond with wild-type alleles, i.e., mismatched base pairing(s) will occur at variation site(s) between the siRNAs and wild-type alleles (Figure 6A; wild-type mRNA).
Previous studies in which the effects of single-nucleotide mismatches in siRNAs on RNAi activities were systematically examined suggest that nucleotide mismatches are able to influence RNAi activity [26,32]. Our present and previous studies indicate that some, but not all, of the designed siRNA duplexes targeting mutant alleles apparently discriminate the mutant alleles from the wild-type alleles. Since different siRNAs confer different levels of RNAi activity depending upon their thermodynamic properties, the intrinsic knockdown potency may also affect allele discrimination between target and non-target alleles.

In the present study, we observed an improvement in ASP-RNAi when siRNAs induced double knockdown of mutant and wild-type alleles: introduction of a one-base substitution into such siRNAs carrying the original variations around the central position appeared to influence allele discrimination and inhibition of target mutant alleles, although different base substitutions conferred different levels of discrimination and inhibition (Figure 6B). This phenomenon may be associated with the thermodynamic properties of the modified siRNA duplexes. Interestingly, the base substitutions conferring marked ASP-RNAi appeared to be largely present in the region of guide siRNAs, corresponding to the seed region of microRNAs. Since such siRNAs exhibit one and two mismatches against mutant and wild-type alleles, respectively, we suggest that disruption of base-pairing interaction in the seed region, as well as the central position, of the guide siRNAs reduces recognition and/or silencing activity against wild-type alleles, and that a one-base mismatch in the seed region of the guide siRNAs against the target mutant alleles hardly affects gene silencing, i.e., potent RNAi activity against the mutant alleles may remain unchanged.

In addition to the improvement in siRNAs conferring double knockdown of mutant and wild-type alleles, we also observed an enhancement of allele discrimination in ASP-RNAi when siRNAs induced weak knockdown potency, which is in contrast to that of the siRNAs described above. In that case, forked siRNA duplexes carrying two nucleotide mismatches at the 3'-ends of the sense-stranded siRNA elements may allow enhanced allele discrimination between target mutant and wild-type alleles. Since forked siRNA duplexes appear to increase the assembly of antisense-strand (guide) siRNA elements into RISCs, the ease of incorporation of antisense-strand siRNA elements into RISCs may be a key factor for improvement of ASP-RNAi activity. Altogether, the evidence presented here suggests that structural modification by introduction of base substitution into siRNA or shRNA sequences could influence allele discrimination and silencing activity in ASP-RNAi.

Figure 5. Different knockdown potencies against HOXB8 between miR-196a and miR-196b. (A) Nucleotide sequences of HOXB8 mRNA, miR-196a and miR-196b. The HOXB8 mRNA sequence, which is nearly complementary to miR-196a, together with mature miR-196a and miR-196b are aligned. Perfect base-pairing and GU wobble base-pairing are indicated by the horizontal bars and dot, respectively. The mismatched base in miR-196b is indicated in red. (B) Effects of miR-196a and miR-196b on gene silencing against HOXB8. The miR-196a and miR-196b duplexes were chemically synthesized, as described previously [31]. The synthetic miRNA duplexes, together with a reporter plasmid carrying a part of the HOXB8 gene (see Materials and Methods), were cotransfected into HeLa cells and the expression of reporter gene was examined. Ratios of normalized target (Renilla) luciferase activity to control (Photinus) luciferase activity are shown. Data are averages of at least three independent experiments. Error bars represent standard deviations.

doi:10.1371/journal.pone.0002248.g005

Properties of siRNA duplexes conferring ASP-RNAi

Based on the assessed siRNA duplexes efficacy of ASP-RNAi, it appears that different siRNA duplexes induce different levels of ASP-RNAi, suggesting that allele-specific knockdown potencies are most likely dependent on the designed siRNA sequences. Previous studies have suggested that functional siRNA duplexes can be characterized by low base-pairing stability at their 3'-ends [29,33–35], i.e., an asymmetrical feature of base-pairing stability occurs between both ends of functional siRNA duplexes. From the alignment of the siRNA sequences examined in the present and previous studies, it was observed that the siRNA duplexes conferring little or no gene silencing possessed symmetrical base-pairing stability and contained G or C residues at many 3'-ends of their sense-stranded elements (supplementary Table s7A); these features are distinct from those of functional siRNA duplexes. In contrast to the above siRNA duplexes, most of the siRNA duplexes triggering strong RNAi activity, including ASP-RNAi, tended to have asymmetrical base-pairing stability (supplementary Table s7B). It may be of interest to elucidate the properties of siRNA duplexes that confer strong ASP-RNAi, other than the asymmetrical feature. To address this, extensive examination of the knockdown potency of siRNA duplexes targeting various mutant alleles is required.

In conclusion, in order to realize ASP-RNAi against target mutant alleles carrying nucleotide variations, the design and evaluation of competent siRNA duplexes conferring ASP-RNAi is vital; but designed siRNAs do not always confer potent ASP-RNAi activity. The evidence presented here suggests that structural modification of siRNA duplexes by base substitutions may improve ASP-RNAi. The key regions in an siRNA duplex for such modifications are the central position, the seed region and the 3'-end of the sense-strand siRNA element, which appear to be related to target RNA cleavage, target RNA recognition and assembly of the antisense-strand (guide)
siRNA element into RISCs, respectively. Therefore, structural modification of such functional portions of siRNA duplexes may greatly influence allele discrimination and gene silencing activity, thereby conferring improvement of ASP-RNAi.

Materials and Methods

Preparation of oligonucleotides
RNA and DNA oligonucleotides were obtained from TAKARA BIO, and INVITROGEN or BEX, respectively. For preparation of duplexes, sense- and antisense-strand oligonucleotides (20 μM each) were mixed and annealed, as described previously [29]. Sequences of synthesized RNA and DNA oligonucleotides are shown in supplementary Tables s1, s2, s3, s4, s5 and s6. Non-silencing siRNA duplex (siControl; Qiagen) was used as the negative control.

Cell culture
HeLa and HEK293 cells were grown at 37°C in Dulbecco’s modified Eagle’s medium (Wako) supplemented with 10% fetal bovine serum (Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin (Wako) in a 5% CO2-humidified chamber. HEK293 cells (Registry No. JCRB9068) were obtained from the Health Science Research Resources Bank.

Construction of reporter alleles and shRNA expression plasmids
Reporter alleles were constructed as described previously [17]. Briefly, phRL-TK (Promega) and pGL3-TK [30] plasmids encoding the Renilla and Photinus luciferase genes, respectively, were digested with XbaI and NotI, and subjected to ligation with synthetic oligonucleotide duplexes corresponding to the PRNP...
PI02L, PRNP-P105L and PRNP-D178N alleles, as well as wild-type alleles (oligonucleotide sequences are indicated in supplementary Table S3). The resultant plasmids carry allelic PRNP sequences in the 3‘ untranslated regions (UTRs) of the h2PC genes (Figure 1A). The London-type APP mutant and wild-type APP reporter alleles described in a previous paper [17] were also used.

For construction of shRNA expression vectors, the GeneSilencer shRNA Vector (Gene Therapy System, Inc.) was used, and synthetic oligonucleotide duplexes were inserted into the vector according to the manufacturer’s instructions (oligonucleotide sequences are indicated in Table S4). To construct a reporter plasmid carrying part of the HOXB8 sequence, psiCHECK-2 vector (Promega) was digested with XhoI and PmeI, and subjected to ligation with synthetic HOXB8 oligonucleotide duplex (supplementary Table S5). With regard to expression plasmids carrying a full-length cDNA of the human PRNP linked with the V5-tag sequence, the wild-type PRNP cDNA was amplified by RT-PCR with human brain total RNA (Ambion), trimmed with EcoRI and NotI, and inserted into the pTracer-EF/Bsd vector (Invitrogen); the resultant plasmid was designated ‘pPRNPwtp-V5’. Using this plasmid, mutant plasmids carrying the PRNP PI02L and PI05L were constructed using the GeneEditor in vitro Site-Directed Mutagenesis System (Promega) and the QuikChange Site-Directed Mutagenesis Kit (Stratagene), respectively, according to the manufacturer’s instructions; the resultant mutant expression plasmids were designated ‘pPRNPmut102-V5’ and ‘pPRNPmut105-V5’. The PCR primers for PRNP cDNA synthesis and oligonucleotides used for the mutagenesis were as follows:

For PRNP cDNA synthesis;
Forward PCR primer: 5’-TTTCGGAATTCGACCATGGC-GAACCTTGGCTGCT-3’
Reverse PCR primer: 5’-ACATTGCGGCCGCTCCCACCAC-TATCGGAAGATGG-3’

For site-directed mutagenesis:
PRNP PI02L oligo DNA;
5’-pGTTGAAACAGCTGTAAGCCCCAA-3’
PRNP PI05L oligo DNAs;
Forward;
5’-GGACACGGCCAGTGAAGCTAAAACCAACAT-GAAGCACATGGC-3’
Reverse;
5’-GCCATGTTGCTCATGTGTTTCTTATCATCTC-GGTTGTTCCC-3’

Transfection and reporter assay

The day before transfection, cells were trypsinized, diluted with fresh medium without antibiotics, and seeded into 24-well culture plates (approximately 0.5 × 10^5 cells/well). Next, 0.24 µg (40 nM) of siRNA duplexes or 0.1 µg of shRNA vectors together with 0.2 µg of pG3-L-TK-backbone plasmid, 0.05 µg of pHRL-TK-backbone plasmid and 0.1 µg of pSV-β-Galactosidase control vector (Promega) as a control were applied to each well using Lipofectamine 2000 transfection reagent (Invitrogen) as described previously [30]. Twenty-four hours after transfection, cell lysate was prepared and expression levels of luciferase and β-galactosidase were examined using the Dual-Luciferase reporter assay system (Promega) and Beta-Glo assay system (Promega), respectively, according to the manufacturer’s instructions. The luminescent signals were measured using a TD-20/20 luminometer (Promega).

Western blotting

The pPRNPwtp-V5 or pPRNPmut102(02) or mut105-V5 plasmid (0.1 µg) was cotransfected with siRNA duplex (0.24 µg) or shRNA expression plasmid (0.1 µg) into HeLa cells. Forty-eight hours after transfection, cell lysate was prepared and examined by Western blotting. Equal amounts of cell lysate were separated by SDS-PAGE and electrophoretically blotted onto PVDF membranes (Millipore). Membranes were blocked for 1 h in blocking solution [5% non-fat milk in washing buffer (0.1% Tween-20 in PBS)] and incubated with anti-V5 antibody (Invitrogen) or anti-α-tubulin antibody DM1A (Sigma), followed by washing in PBS containing 0.1% Tween-20 and further incubation with horseradish peroxidase-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories). Antigen-antibody complexes were visualized using Immobilon Western reagent (Millipore). The experiments were duplicated at least twice independently.

Supporting Information

Figure S1 Wild-type and mutant PRNP mRNAs and designed sense-strand siRNAs. The wild-type and mutant PRNP mRNA sequences around the P102L (A), P105L (B), and D178N (C) variations, respectively, are shown and the nucleotide variations are indicated in red. Designed siRNAs (indicated) are represented by thin lines and only the variations are indicated in red.
Found at: doi:10.1371/journal.pone.0002248.s001 (0.26 MB TIF)

Figure S2 Expression of the wild-type (A) and PI02L (B) PRNP polypeptides in the presence of indicated siRNAs was examined by Western blotting as in Figure 2. Expression of α-tubulin was also examined as the control.
Found at: doi:10.1371/journal.pone.0002248.s002 (0.99 MB TIF)

Figure S3 Assessment of mismatched siPrnp102(T10) and siPrnp178(A9) on ASP-RNAi. (A, D) Nucleotide sequences of wild-type and mutant PRNP mRNAs and designed siRNAs are indicated as in Figure 2. (B, E) Assessment of mismatched siRNAs was carried out and the results are shown as in Figure 2. (C, F) Western blot analysis of the wild-type PRNP polypeptide (PRNPwtp-V5) in the presence of indicated siRNAs was carried out as in Figure 2. The PRNPwtp-V5 gene was driven by the EF-1α promoter instead of the CMV promoter in this experiment. Expression of α-tubulin was also examined as the control.
Found at: doi:10.1371/journal.pone.0002248.s003 (0.61 MB TIF)

Table S1
Found at: doi:10.1371/journal.pone.0002248.s004 (0.04 MB DOC)

Table S2
Found at: doi:10.1371/journal.pone.0002248.s005 (0.05 MB DOC)

Table S3
Found at: doi:10.1371/journal.pone.0002248.s006 (0.03 MB DOC)

Table S4
Found at: doi:10.1371/journal.pone.0002248.s007 (0.03 MB DOC)

Table S5
Found at: doi:10.1371/journal.pone.0002248.s008 (0.04 MB DOC)

Table S6
Found at: doi:10.1371/journal.pone.0002248.s009 (0.03 MB DOC)

Table S7
Found at: doi:10.1371/journal.pone.0002248.s010 (0.11 MB DOC)
Author Contributions
Conceived and designed the experiments: HH YO. Performed the experiments: HH YO YT MY. Analyzed the data: HH YO YT.

References
1. Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4: 457–467.
2. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
3. Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363–366.
4. Matranga C, Tomari Y, Shin C, Barrel DP, Zamore PD (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123: 607–620.
5. Paddison PJ, Silva JM, Conklin DS, Schlabach M, Li M, et al. (2004) A resource for large-scale RNA-interference-based screens in mammals. Nature 428: 427–431.
6. Caplen NJ (2004) Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther 11: 1241–1248.
7. Karagiannis TC, El-Osta A (2005) RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther 12: 707–705.
8. Bonini NM, La Spada AR (2005) Silencing polyglutamine degeneration with RNAi. Neuron 48: 715–718.
9. Victor M, Ben Y, Gay F, Calvo D, Mello C, et al. (2002) HAT activity is essential for CBP-1-dependent transcription and differentiation in Caenorhabditis elegans. EMBO Rep 3: 50–55.
10. Wood M, Yin H, McClory G (2007) Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 3: e109.
11. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, et al. (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 100: 7195–7200.
12. Miller VM, Gouvion CM, Davidson BL, Paulson HL (2004) Targeting Alzheimer’s disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 32: 661–668.
13. Rodriguez-Lebron E, Paulson HL (2006) Allele-specific RNA interference for neurological disease. Gene Ther 13: 576–581.
14. Maxwell MM, Paesini P, Kazantsev AG, Brown JR (2004) RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells. Proc Natl Acad Sci U S A 101: 7915–7920.
15. Miller VM, Gouvion CM, Davidson BL, Paulson HL (2004) Targeting Alzheimer’s disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 32: 661–668.
16. Rodriguez-Lebron E, Paulson HL (2006) Allele-specific RNA interference for neurological disease. Gene Ther 13: 576–581.
17. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
18. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
19. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
20. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
21. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
22. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
23. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
24. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
25. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
26. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
27. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
28. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
29. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
30. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
31. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
32. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
33. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
34. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
35. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
36. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
37. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
38. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
39. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
40. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
41. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
42. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
43. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
44. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
45. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
46. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
47. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
48. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
49. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
50. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.